NextCure (NXTC) Expected to Announce Earnings on Thursday

NextCure (NASDAQ:NXTC) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect NextCure to post earnings of ($0.35) per share for the quarter.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). On average, analysts expect NextCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NextCure Stock Performance

Shares of NextCure stock opened at $0.58 on Wednesday. The stock has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.07. NextCure has a one year low of $0.58 and a one year high of $2.57. The stock has a market cap of $16.19 million, a price-to-earnings ratio of -0.28 and a beta of 0.71.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of NextCure in a report on Monday.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.